Chemoprevention of Cancer

1. Front Matter

   Pages I-IX

   PDF

2. Smoking, Genetics and Cancer

   1. Front Matter

      Pages 1-1

      PDF

   2. Is There a Genetic Basis for Lung Cancer Susceptibility?

      • C. I. Amos, W. Xu, M. R. Spitz

      Pages 3-12

   3. Chemoprevention of Head and Neck and Lung (Pre)Cancer

      • N. de Vries, N. van Zandwijk, U. Pastorino

      Pages 13-25

3. Targets and Markers for Cancer Prevention

   1. Front Matter

      Pages 27-27

      PDF

   2. Rationale and Mechanisms of Cancer Chemoprevention

      • S. De Flora, C. Bennicelli, M. Bagnasco

      Pages 29-44

   3. Metabolic Targets of Cancer Chemoprevention: Interruption of Tumor Development by Inhibitors of Arachidonic Acid Metabolism

      • F. Marks, G. Fürstenberger, K. Müller-Decker

      Pages 45-67

4. Identification of Meaningful High Risk Groups for Cancer Chemoprevention

   1. Front Matter

      Pages 69-69

      PDF

   2. Prognostic Implications of Cancer Susceptibility Genes: Any News?

      • R. J. Scott, H. H. Sobol

      Pages 71-84

   3. Identification of the Woman at Risk for Breast Cancer: Problem Solved?

      • M. Morrow

      Pages 85-95

   4. Development of a New Prevention Maintenance Therapy for Postmenopausal Women

      • V. Craig Jordan

      Pages 96-109

5. Clinical Cancer Chemoprevention

   1. Front Matter

      Pages 111-111

      PDF

   2. Chemoprevention of Human Cancer:A Reasonable Strategy?

      • Frank L. Meyskens Jr.

      Pages 113-121

   3. Chemoprevention of Colorectal Cancer

      • J. Faivre, C. Bonithon-Kopp

      Pages 122-133

Pharmacologic interventions to prevent the evolution of human cancers are still in its infancy, although a good number o- mostly controlled - clinical studies have been performed in the past two decades. However, regarding the partially stagnating therapeutic results of major epithelial cancer types such as breast-, lung-, colon- and ENT-cancer types, the problem of in­ terference with the evolution of disease at a preclinical level is an intriguing one, and the field seems to develop into one of the fastest growing domaines of modern oncology. This process is fa­ cilitated by the developments of molecular on co-genetics and the gowing existence of family cancer units, allowing to better identi­ fy and inform respective high risk groups, thus enabling re­ searchers and clinicians to more realistically target their chemo­ preventive efforts to the true populations at risk. On this changing background, the newly formed International Society of Cancer Chemoprevention (ISCaC) together with the Swiss Cancer League and the Interdisciplinary Oncology Center of St. Gallen/Switzerland organized an international Symposium in September 1997, inviting basic researchers, epidemiologists and clinical oncologists of related disciplines to discuss pertinent issues of experimental and clinical chemo- and bio-prevention in a scientific workshop.

• bioprevention of cancer
• breast cancer
• cancer
• cancer prevention
• chemoprevention
• colorectal cancer
• genetics
• lung cancer
• pharmacology
• prevention
• tumor

• Center for Tumordetection and Prevention, St. Gallen, Switzerland

  Hans-Jörg Senn

• European Institute of Oncology, Milan, Italy

  Alberto Costa

• Robert H. Lurie Cancer Center Breast Cancer Research Program, Olson Pavilion, Northwest-University Medical School, Chicago, USA

  V. Craig Jordan

Policies and ethics